Picture of Vertex Pharmaceuticals logo

VRTX — Vertex Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Momentum

Relative Strength (%)
1m+4.61%
3m+29.63%
6m+72.61%
1yr+36.82%
Volume Change (%)
10d/3m-10.95%
Price vs... (%)
52w High-7.48%
50d MA+2.8%
200d MA+22.54%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)18.41
PEG Ratio (f)0.75
EPS Growth (f)32.51%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value6.35
Price to Tang. Book7.29
Price to Free Cashflow28.26
Price to Sales8.72
EV to EBITDA20.06

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital24.31%
Return on Equity24.65%
Operating Margin36.93%

Financial Summary

Year End 31st DecUnit201720182019202020212022E2023ECAGR / Avg
Total Revenue$m2,488.653,047.64,162.826,205.687,574.48,591.049,190.9134.79%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%n/a+25.17+108.98+127.31-12.57+58.32+8.05n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for VRTX

Stock market volatility: Is this large-cap worth a closer look? background image

Stock market volatility: Is this large-cap worth a closer look?

Shares in Vertex Pharmaceuticals Inc (NSQ:VRTX) are currently trading at $266.2 but a key question for investors is how much a prolonged spell of economic uncertainty will impact the price. The answer comes down to judging whether Vert...

The Vertex Pharmaceuticals Inc share price – where next? background image

The Vertex Pharmaceuticals Inc share price – where next?

The Vertex Pharmaceuticals Inc (NSQ:VRTX) share price has risen by 4.65% over the past month and it’s currently trading at 272.82. For investors considering whether to buy, hold or sell the stock, the question now is whether this price...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Vertex Pharmaceuticals EPS forecast chart

Profile Summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The Company's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The Company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
January 4th, 1989
Public Since
July 24th, 1991
No. of Shareholders
107
No. of Employees
3,900
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
255,755,961

VRTX Share Price Performance

Latest News for VRTX

Upcoming Events for VRTX

Q2 2022 Vertex Pharmaceuticals Inc Earnings Release

Q3 2022 Vertex Pharmaceuticals Inc Earnings Release

Similar to VRTX

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of ACADIA Pharmaceuticals logo

ACADIA Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email